his strategic collaboration with BluSim Tech marks a significant milestone in Fischer MVL's journey towards expanding its healthcare portfolio
Sleep disturbances are among the most frequent and disruptive symptoms associated with menopause which can impact women’s health and quality of life
This novel recombinant has been developed and is a patented novel recombinant Human Albumin 20% process
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
Facility in The Woodlands, Texas to produce critical starting material for cell and gene therapy, DNA/RNA-based, and recombinant protein therapeutics in Q1/2025
Acceptance based on results demonstrated a statistically significant improvement in overall survival versus chemotherapy alone in these patients
Sacubitril and Valsartan Tablets are indicated to reduce the risk of cardiovascular death
Subscribe To Our Newsletter & Stay Updated
